EcoDrugPlus

Nadph Oxidase 4

Ensembl ID : ENSMZEG00005023671
Gene Symbol: NOX4
4 Cross references
150 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSMZEG00005010178
Gene Symbol: NPC1L1
4 Cross references
189 Possible Orthologues:

P2x Purinoceptor 3

Ensembl ID : ENSMZEG00005013789
Gene Symbol: LOC101463859
3 Cross references
195 Possible Orthologues:

P2x Purinoceptor 3

Ensembl ID : ENSMZEG00005003165
Gene Symbol: LOC101466017
3 Cross references
192 Possible Orthologues:

P2y Purinoceptor 12

Ensembl ID : ENSMZEG00005001169
Gene Symbol: LOC101467746
3 Cross references
180 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMZEG00005012371
Gene Symbol: PIM1
3 Cross references
246 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMZEG00005015428
Gene Symbol: PIM3
3 Cross references
172 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSMZEG00005023498
Gene Symbol: LOC101466452
3 Cross references
161 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSMZEG00005013854
Gene Symbol: LOC101480630
3 Cross references
209 Possible Orthologues:

Rac-Gamma Serine/threonine-Protein Kinase

Ensembl ID : ENSMZEG00005027393
Gene Symbol: LOC101476427
3 Cross references
203 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSMZEG00005008549
Gene Symbol: RELA
3 Cross references
199 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMZEG00005025919
Gene Symbol: RAF1
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).